ImmunoCellular Therapeutics Ltd (NYSE American:IMUC)

0.2644
Delayed Data
As of 3:53pm ET
 -0.0025 / -0.92%
Today’s Change
0.17
Today|||52-Week Range
2.79
-16.33%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$12.2M

Company Description

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.

Contact Information

ImmunoCellular Therapeutics Ltd.
30721 Russell Ranch Road
Westlake Village California 91362
P:(818) 264-2300
Investor Relations:

Employees

Shareholders

Other institutional5.02%
Mutual fund holders0.70%
Individual stakeholders0.30%

Top Executives

Gary S. TitusChairman & Secretary
Anthony J. GringeriPresident, Chief Executive Officer & Director
David E. FractorChief Financial Officer
Steven J. SwansonSenior Vice President-Research